Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure*
- 1 August 2006
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 34 (8) , 2140-2144
- https://doi.org/10.1097/01.ccm.0000229144.97624.90
Abstract
B-type natriuretic peptide (BNP) and N-terminal pro-BNP measurements are used for the diagnosis of congestive heart failure (HF). However, the diagnostic value of these tests is unknown under septic conditions. We compared patients with severe sepsis or septic shock and patients with acute HF to unravel the influence of the underlying diagnosis on BNP and N-terminal pro-BNP levels. Prospective, clinical study. Academic medical intensive care unit (ICU). A total of 249 consecutive patients were screened for the diagnosis of sepsis or HF. Sepsis was defined according to published guidelines. HF was diagnosed in the presence of an underlying heart disease and congestive HF, pulmonary edema, or cardiogenic shock. BNP and N-terminal pro-BNP were measured from blood samples that were drawn daily for routine analysis. We identified 24 patients with severe sepsis or septic shock and 51 patients with acute HF. At admission, the median (range) BNP and N-terminal pro-BNP levels were 572 (13-1,300) and 6,526 (198-70,000) ng/L in patients with sepsis and 581 (6-1,300) and 4,300 (126-70,000) ng/L in patients with HF. The natriuretic peptide levels increased during the ICU stay, but the differences between the groups were not significant. Nine patients with sepsis and eight patients with HF were monitored with a pulmonary artery catheter. Mean (sd) pulmonary artery occlusion pressure were 16 (4.2) and 22 (5.3) mm Hg (p = .02), and cardiac indexes were 4.6 (2.8) and 2.2 (0.6) L/min/m (p = .03) in patients with sepsis and HF, respectively. Despite these clear hemodynamic differences BNP and N-terminal pro-BNP levels were not statistically different between the two groups. In patients with severe sepsis or septic shock, BNP and N-terminal pro-BNP values are highly elevated and, despite significant hemodynamic differences, comparable with those found in acute HF patients. It remains to be determined how elevations of natriuretic peptide levels are linked to inflammation and sepsis-associated myocardial dysfunction.Keywords
This publication has 34 references indexed in Scilit:
- The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) studyThe American Journal of Cardiology, 2005
- Brain and other natriuretic peptides: molecular aspectsEuropean Journal of Heart Failure, 2004
- Essential biochemistry and physiology of (NT‐pro)BNPPublished by Wiley ,2004
- Use of NT‐proBNP in routine testing and comparison to BNPEuropean Journal of Heart Failure, 2004
- Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute DyspneaNew England Journal of Medicine, 2004
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureNew England Journal of Medicine, 2002
- Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrationsThe Lancet, 2000
- Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload.Journal of Clinical Investigation, 1995
- Plasma brain natriuretic peptide in assessment of acute dyspnoeaThe Lancet, 1994
- Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.Journal of Clinical Investigation, 1991